Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Structural Basis of Catalysis and Inhibition of HDAC6 CD1, the Enigmatic Catalytic Domain of Histone Deacetylase 6
J.D. Osko, D.W. Christianson
Biochemistry (2019) Vol. 58, Iss. 49, pp. 4912-4924
Open Access | Times Cited: 59

Showing 1-25 of 59 citing articles:

Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight
Terence C. S. Ho, Alex H. Y. Chan, A. Ganesan
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 21, pp. 12460-12484
Open Access | Times Cited: 566
HDAC6 as privileged target in drug discovery: A perspective
Sravani Pulya, Sk. Abdul Amin, Nilanjan Adhikari, et al.
Pharmacological Research (2020) Vol. 163, pp. 105274-105274
Closed Access | Times Cited: 179
A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity
Xin-Hui Zhang, Qin-Ma, Hui-Pan Wu, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 3, pp. 1362-1391
Closed Access | Times Cited: 106
Charcot-Marie-tooth disease type 2A: An update on pathogenesis and therapeutic perspectives
Claudia Alberti, Federica Rizzo, Alessia Anastasia, et al.
Neurobiology of Disease (2024) Vol. 193, pp. 106467-106467
Open Access | Times Cited: 15
Strategies To Design Selective Histone Deacetylase Inhibitors
Jelena Melesina, Conrad V. Simoben, Lucas Praetorius, et al.
ChemMedChem (2021) Vol. 16, Iss. 9, pp. 1336-1359
Closed Access | Times Cited: 84
Solid-Phase Synthesis of Cereblon-Recruiting Selective Histone Deacetylase 6 Degraders (HDAC6 PROTACs) with Antileukemic Activity
Laura Sinatra, Jing Yang, Julian Schliehe‐Diecks, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 24, pp. 16860-16878
Open Access | Times Cited: 42
Groebke Blackburn Bienaymé-mediated multi-component synthesis of selective HDAC6 inhibitors with anti-inflammatory properties
Fabian B. Kraft, Jana Enns, Irina Honin, et al.
Bioorganic Chemistry (2024) Vol. 143, pp. 107072-107072
Closed Access | Times Cited: 8
Histone deacetylases as targets for the treatment of neurodegenerative disorders: Challenges and future opportunities
Daniel A. Rodrigues, Pedro de Sena Murteira Pinheiro, Fernanda S. Sagrillo, et al.
Medicinal Research Reviews (2020) Vol. 40, Iss. 6, pp. 2177-2211
Closed Access | Times Cited: 55
Curriculum vitae of HDAC6 in solid tumors
Yi‐Chao Zheng, Huiqin Kang, Bo Wang, et al.
International Journal of Biological Macromolecules (2023) Vol. 230, pp. 123219-123219
Closed Access | Times Cited: 19
Difluoromethyl-1,3,4-oxadiazoles are slow-binding substrate analog inhibitors of histone deacetylase 6 with unprecedented isotype selectivity
Edoardo Cellupica, Gianluca Caprini, Paola Cordella, et al.
Journal of Biological Chemistry (2022) Vol. 299, Iss. 1, pp. 102800-102800
Open Access | Times Cited: 22
Recent development of selective inhibitors targeting the HDAC6 as anti-cancer drugs: Structure, function and design
Jie Peng, Fei Xie, Pengxia Qin, et al.
Bioorganic Chemistry (2023) Vol. 138, pp. 106622-106622
Open Access | Times Cited: 13
Pharmacological inhibition of HDAC6 suppresses NLRP3 inflammasome-mediated IL-1β release
Judith Bockstiegel, Silas Wurnig, Jonas Engelhardt, et al.
Biochemical Pharmacology (2023) Vol. 215, pp. 115693-115693
Closed Access | Times Cited: 13
Structure similarity based screening coupled to integrated structural biochemistry approach for exploring the high affinity inhibitors against histone deacetylase (HDAC)-6
Shabir Ahmad Ganai, Suma Mohan
In Silico Pharmacology (2025) Vol. 13, Iss. 1
Closed Access
Acute myeloid leukemia with t(8;21) translocation: Molecular pathogenesis, potential therapeutics and future directions
Pei Han Yu, Ze Yan Zhang, Yuan Yuan Kang, et al.
Biochemical Pharmacology (2025) Vol. 233, pp. 116774-116774
Closed Access
Design and synthesis of novel HDAC6 inhibitor dimer as HDAC6 degrader for cancer treatment by palladium catalysed dimerisation
Ching Lin, Jui‐Ling Hsu, Yu‐Tung Hsu, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2025) Vol. 40, Iss. 1
Open Access
Monoselective Histone Deacetylase 6 PROTAC Degrader Shows In Vivo Tractability
Harsimran Kaur Garcha, Olasunkanmi O. Olaoye, Abootaleb Sedighi, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Structural determinants of affinity and selectivity in the binding of inhibitors to histone deacetylase 6
J.D. Osko, D.W. Christianson
Bioorganic & Medicinal Chemistry Letters (2020) Vol. 30, Iss. 8, pp. 127023-127023
Open Access | Times Cited: 38
Bifunctional HDAC Therapeutics: One Drug to Rule Them All?
Joshua P. Smalley, Shaun M. Cowley, James T. Hodgkinson
Molecules (2020) Vol. 25, Iss. 19, pp. 4394-4394
Open Access | Times Cited: 38
Development of Fluorinated Peptoid-Based Histone Deacetylase (HDAC) Inhibitors for Therapy-Resistant Acute Leukemia
Nina Reßing, Julian Schliehe‐Diecks, P. R. Watson, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 22, pp. 15457-15472
Open Access | Times Cited: 21
HDAC6 inhibition: a significant potential regulator and therapeutic option to translate into clinical practice in renal transplantation
Qianqian Zhang, Weijie Zhang, Sheng Chang
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
Engineering novel scaffolds for specific HDAC11 inhibitors against metabolic diseases exploiting deep learning, virtual screening, and molecular dynamics simulations
Jiali Li, XiaoDie Chen, Rong Liu, et al.
International Journal of Biological Macromolecules (2024) Vol. 262, pp. 129810-129810
Closed Access | Times Cited: 4
A comprehensive review of small molecule drugs approved by the FDA in 2024: Advance and prospect
Yi‐Ru Bai, Qingchuan Duan, Dong‐Jie Seng, et al.
Chinese Chemical Letters (2025), pp. 111025-111025
Closed Access
Mercaptoacetamide: A promising zinc-binding group for the discovery of selective histone deacetylase 6 inhibitors
Maurício T. Tavares, Alan P. Kozikowski, Sida Shen
European Journal of Medicinal Chemistry (2020) Vol. 209, pp. 112887-112887
Open Access | Times Cited: 32
Structural basis for the regulation of nucleosome recognition and HDAC activity by histone deacetylase assemblies
Jung‐Hoon Lee, Daniel Bollschweiler, Tillman Schäfer, et al.
Science Advances (2021) Vol. 7, Iss. 2
Open Access | Times Cited: 25
Technologies of targeting histone deacetylase in drug discovery: Current progress and emerging prospects
Jinxiao Ru, Yuxi Wang, Zijia Li, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115800-115800
Closed Access | Times Cited: 10
Page 1 - Next Page

Scroll to top